Defining orphan conditions in the context of the European orphan regulation: challenges and evolution

Tools

Item Type:	Editorial
Title:	Defining orphan conditions in the context of the European orphan regulation: challenges and evolution
Creators Name:	O'Connor, D.J., Sheean, M.E., Hofer, M.P., Tsigkos, S., Mariz, S., Fregonese, L., Larsson, K., Hivert, V., Westermark, K., Naumann-Winter, F., Stoyanova-Beninska, V., Barišić, I., Capovilla, G., Magrelli, A. and Sepodes, B.
Abstract:	The definition and acceptability of an orphan condition is pivotal for the assessment of European orphan medicinal product designation applications, and consequently the eligibility for incentives. Here, based on the experiences of the Committee for Orphan Medicinal Products, we discuss how to define orphan conditions in the context of the European regulatory framework.
Keywords:	Drug Development, Drug Legislation, European Union, Government Regulation, Orphan Drug Production, Rare Diseases
Source:	Nature Reviews Drug Discovery
ISSN:	1474-1776
Publisher:	Nature Publishing Group
Volume:	18
Number:	7
Page Range:	479-480
Date:	July 2019
Official Publication:	https://doi.org/10.1038/nrd.2018.128
PubMed:	View item in PubMed

Repository Staff Only: item control page